JANSSEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN
JANSSEN has eighty-one approved drugs.
There are eighty-one US patents protecting JANSSEN drugs.
There are two thousand one hundred and seventy-eight patent family members on JANSSEN drugs in sixty-four countries and three hundred and sixty-eight supplementary protection certificates in twenty-one countries.
Summary for JANSSEN
| International Patents: | 2178 |
| US Patents: | 81 |
| Tradenames: | 77 |
| Ingredients: | 52 |
| NDAs: | 81 |
| Patent Litigation for JANSSEN: | See patent lawsuits for JANSSEN |
| PTAB Cases with JANSSEN as patent owner: | See PTAB cases with JANSSEN as patent owner |
Drugs and US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | CONCERTA | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021121-001 | Aug 1, 2000 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Janssen Pharms | INVEGA HAFYERA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-006 | Aug 30, 2021 | RX | Yes | Yes | 11,666,697 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-002 | Aug 19, 2024 | RX | Yes | Yes | 9,593,098 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | AB | RX | Yes | No | 12,303,493 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | RAZADYNE | galantamine hydrobromide | TABLET;ORAL | 021169-002 | Feb 28, 2001 | 6,099,863 | ⤷ Start Trial |
| Janssen Pharms | RISPERDAL | risperidone | SOLUTION;ORAL | 020588-001 | Jun 10, 1996 | RE39181*PED | ⤷ Start Trial |
| Janssen Pharms | INVEGA | paliperidone | TABLET, EXTENDED RELEASE;ORAL | 021999-001 | Dec 19, 2006 | 5,158,952*PED | ⤷ Start Trial |
| Janssen Pharma | NIZORAL | ketoconazole | CREAM;TOPICAL | 019084-001 | Dec 31, 1985 | 4,942,162 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
| ➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
| ➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
| ➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
| ➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
| ➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
| ➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
| ➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
| ➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
| ➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
| ➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
| ➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
| ➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
International Patents for JANSSEN Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2012531277 | ⤷ Start Trial |
| Serbia | 61980 | ⤷ Start Trial |
| Ukraine | 37801 | ⤷ Start Trial |
| Japan | 5317951 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JANSSEN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2109608 | 132018000000263 | Italy | ⤷ Start Trial | PRODUCT NAME: NIRAPARIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, UN SUO STEREOISOMERO O TAUTOMERO, IN PARTICOLARE IL TOSILATO O UN IDRATO, IN PARTICOLARE IL TOSILATO MONOIDRATO(ZEJULA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1235, 20171120 |
| 2368550 | 300993 | Netherlands | ⤷ Start Trial | PRODUCT NAME: APALUTAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1342 20190116 |
| 1214076 | SZ 49/2008 | Austria | ⤷ Start Trial | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| 1713823 | 300703 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SIMEPREVIR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, WAARONDER SIMEPREVIRNATRIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
